Johan Jendle

Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Johan Jendle, Michael A. Nauck, David R. Matthews et al. · Diabetes Obesity and Metabolism · 2009 · 295 citations · Full text

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 286 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +9

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

David C. Klonoff, Jing Wang, David Rodbard et al. · Journal of Diabetes Science and Technology · 2022 · 254 citations · Full text

Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study

Isabelle Isa Kristin Steineck, J. Cederholm, Björn Eliasson et al. · BMJ · 2015 · 244 citations · Full text

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

Lawrence Blonde, Johan Jendle, Jorge Luiz Gross et al. · The Lancet · 2015 · 218 citations

Diabetes Management, Medicine, Insulin Management +8